We have located links that may give you full text access.
EVALUATION STUDIES
JOURNAL ARTICLE
[Midterm results of Oxford phase 3 unicondylar knee arthroplasty for medial osteoarthritis].
Acta Orthopaedica et Traumatologica Turcica 2007 November
OBJECTIVES: We evaluated midterm results of Oxford phase 3 unicondylar knee arthroplasty (UKA) in patients with medial osteoarthritis.
METHODS: Twenty-seven patients (24 females, 3 males; mean age 57 years; range 47 to 73 years) underwent Oxford phase 3 UKA with the diagnosis of medial knee osteoarthritis. All patients had primary osteoarthritis but one with spontaneous osteonecrosis. Nine knees were Ahlback grade 2, and 18 knees were grade 3. All femoral and tibial components were cemented and mobile tibial polyethylene inserts were used in all the patients. Pre- and postoperative evaluations were made using the Knee Society clinical rating system. The mean follow-up was 28 months (range 24 to 36 months).
RESULTS: Compared to the preoperative values, significant improvements were obtained in the following at final follow-up (p<0.05): knee flexion (106.4 degrees and 117.4 degrees , respectively), tibiofemoral angle (7 degrees varus and 1 degrees valgus), knee score (47.5 and 78.9), and functional knee score (48.7 and 83.6). Only two patients needed blood transfusion. No major complications occurred including infection, deep vein thrombosis, pulmonary emboli, and neurovascular injury. Two patients underwent revision surgery at postoperative 8 and 10 months, respectively, because of progressive collapse of the tibial plateau. Knee Society clinical scores were excellent or good in 21 (77.8%), moderate in four (14.8%), and poor in two (7.4%) patients. The corresponding figures for functional results were 23 (85.2%), 2 (7.4%), and 2 (7.4%).
CONCLUSION: Our results demonstrate that Oxford phase 3 UKA is effective with considerable success in the treatment of medial osteoarthritis.
METHODS: Twenty-seven patients (24 females, 3 males; mean age 57 years; range 47 to 73 years) underwent Oxford phase 3 UKA with the diagnosis of medial knee osteoarthritis. All patients had primary osteoarthritis but one with spontaneous osteonecrosis. Nine knees were Ahlback grade 2, and 18 knees were grade 3. All femoral and tibial components were cemented and mobile tibial polyethylene inserts were used in all the patients. Pre- and postoperative evaluations were made using the Knee Society clinical rating system. The mean follow-up was 28 months (range 24 to 36 months).
RESULTS: Compared to the preoperative values, significant improvements were obtained in the following at final follow-up (p<0.05): knee flexion (106.4 degrees and 117.4 degrees , respectively), tibiofemoral angle (7 degrees varus and 1 degrees valgus), knee score (47.5 and 78.9), and functional knee score (48.7 and 83.6). Only two patients needed blood transfusion. No major complications occurred including infection, deep vein thrombosis, pulmonary emboli, and neurovascular injury. Two patients underwent revision surgery at postoperative 8 and 10 months, respectively, because of progressive collapse of the tibial plateau. Knee Society clinical scores were excellent or good in 21 (77.8%), moderate in four (14.8%), and poor in two (7.4%) patients. The corresponding figures for functional results were 23 (85.2%), 2 (7.4%), and 2 (7.4%).
CONCLUSION: Our results demonstrate that Oxford phase 3 UKA is effective with considerable success in the treatment of medial osteoarthritis.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app